Commitments and Contingencies (Details) |
1 Months Ended | 3 Months Ended | ||||
|---|---|---|---|---|---|---|
Sep. 30, 2020 |
Jan. 31, 2020
shares
|
Mar. 31, 2024
USD ($)
|
Mar. 31, 2023
USD ($)
|
Dec. 31, 2023
USD ($)
|
Dec. 30, 2022
patent
|
|
| Loss Contingencies [Line Items] | ||||||
| Indemnification liability recorded during the period | $ 0 | $ 0 | ||||
| Number of additional patents added to the infringement claims | patent | 3 | |||||
| Estimated litigation liability | 0 | $ 0 | ||||
| Teoxane Agreement | ||||||
| Loss Contingencies [Line Items] | ||||||
| Issuance of common stock in connection with the teoxane agreement (in shares) | shares | 2,500,000 | |||||
| Collaborative agreement, contractual period | 10 years | |||||
| Collaborative agreement, extended contractual period | 2 years | |||||
| Purchase obligation, to be paid, year one | 52,000,000 | |||||
| Minimum expenditures related to commercialization 2024 | 36,000,000 | |||||
| Botulinum Toxin Research Associates, Inc. | ||||||
| Loss Contingencies [Line Items] | ||||||
| Accrued milestone obligations | $ 15,500,000 | |||||